CRIS Current Research Information System

ARDIZZONI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.203
AS - Asia 12.448
EU - Europa 9.585
AF - Africa 889
SA - Sud America 861
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 4
Totale 39.020
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.069
SG - Singapore 3.709
CN - Cina 3.496
VN - Vietnam 2.758
GB - Regno Unito 2.507
IT - Italia 2.011
DE - Germania 1.304
HK - Hong Kong 979
SE - Svezia 884
IN - India 817
BR - Brasile 634
RU - Federazione Russa 621
FR - Francia 426
IE - Irlanda 419
NL - Olanda 376
ZA - Sudafrica 261
KR - Corea 254
TG - Togo 238
EE - Estonia 212
CI - Costa d'Avorio 180
CH - Svizzera 179
FI - Finlandia 178
UA - Ucraina 163
SC - Seychelles 109
AR - Argentina 92
ID - Indonesia 90
JO - Giordania 79
JP - Giappone 73
CA - Canada 69
AT - Austria 67
BG - Bulgaria 66
MX - Messico 54
EC - Ecuador 51
NG - Nigeria 46
BE - Belgio 34
PL - Polonia 30
BD - Bangladesh 29
AU - Australia 26
ES - Italia 26
TR - Turchia 25
CO - Colombia 24
IQ - Iraq 18
PY - Paraguay 18
UZ - Uzbekistan 18
LB - Libano 17
VE - Venezuela 15
CL - Cile 14
GR - Grecia 14
DZ - Algeria 12
EG - Egitto 11
IR - Iran 11
LT - Lituania 11
PK - Pakistan 10
HR - Croazia 9
IL - Israele 9
MY - Malesia 8
SA - Arabia Saudita 7
HU - Ungheria 6
KZ - Kazakistan 6
RO - Romania 6
UY - Uruguay 6
CZ - Repubblica Ceca 5
KE - Kenya 5
MA - Marocco 5
TN - Tunisia 5
AZ - Azerbaigian 4
KG - Kirghizistan 4
MK - Macedonia 4
OM - Oman 4
PE - Perù 4
PT - Portogallo 4
TH - Thailandia 4
AL - Albania 3
BY - Bielorussia 3
ET - Etiopia 3
EU - Europa 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
SM - San Marino 3
SN - Senegal 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
GA - Gabon 2
GT - Guatemala 2
KW - Kuwait 2
LU - Lussemburgo 2
MU - Mauritius 2
PA - Panama 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
VC - Saint Vincent e Grenadine 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
Totale 38.999
Salva come PNG Salva come JPEG
Città #
Singapore 2.379
Southend 2.227
Fairfield 1.891
Ashburn 1.623
Houston 1.000
Hong Kong 968
Chandler 965
Woodbridge 945
Seattle 816
Wilmington 798
Cambridge 685
Dong Ket 614
Santa Clara 602
Princeton 581
Hefei 557
Beijing 527
Ho Chi Minh City 495
Bologna 492
Boardman 465
Hanoi 418
Dublin 417
Ann Arbor 411
Seoul 250
Shanghai 239
Lomé 238
Westminster 228
Los Angeles 214
Nanjing 214
Abidjan 180
Dallas 175
Padova 170
San Diego 144
Bern 141
Redondo Beach 133
Helsinki 125
Berlin 122
Buffalo 121
Milan 120
Redmond 119
Jinan 117
Shenyang 114
New York 112
Medford 109
Saint Petersburg 107
Changsha 88
Turin 85
Tianjin 84
Amman 79
Nanchang 73
São Paulo 71
Bengaluru 64
Visakhapatnam 64
Munich 62
Sofia 61
Hebei 60
Falls Church 59
Rome 59
Frankfurt am Main 56
Tokyo 53
Da Nang 50
Jiaxing 50
Zhengzhou 50
Guangzhou 49
Bremen 48
Florence 48
Jakarta 48
Chicago 46
Abeokuta 45
London 45
Nuremberg 45
Redwood City 45
Haiphong 44
Bühl 43
Dearborn 43
Norwalk 40
Vienna 40
Des Moines 39
Biên Hòa 35
Ha Long 34
Hangzhou 34
Brussels 33
Phoenix 33
Hải Dương 32
Lappeenranta 31
Ninh Bình 30
Olalla 30
Yubileyny 30
Ningbo 29
Taiyuan 29
Falkenstein 28
Vũng Tàu 28
Modena 27
Vicenza 27
Quận Bình Thạnh 26
Toronto 26
Wuhan 26
Hyderabad 25
Quận Một 25
Shenzhen 24
Johannesburg 23
Totale 25.869
Salva come PNG Salva come JPEG
Nome #
Transdermal Fentanyl in Patients with Cachexia-A Scoping Review 602
IFN-γ and CD38 in Hyperprogressive Cancer Development 377
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer 360
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event 247
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC 238
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 237
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 228
CLINICOPATHOLOGICAL, MOLECULAR AND ONCOLOGICAL FEATURES OF SPORADIC EARLY ONSET COLORECTAL CANCERS 219
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC) 214
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 212
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 207
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 199
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 194
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 193
Next-generation technologies in predictive molecular pathology of lung cancers 193
Circulating tumor cells in genitourinary tumors 191
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 187
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 182
A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy 182
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study 179
A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. 179
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 179
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 176
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 173
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 172
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer 172
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 169
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer 168
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 168
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 168
The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 168
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury 167
Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases 166
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST 165
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 164
Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma 162
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 160
Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer 159
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence 158
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 158
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 158
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) 157
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches 157
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 156
Clinical significance of ROS1 5’ deletions in non-small cell lung cancer 155
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 151
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 150
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer 150
Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins 150
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 150
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 150
Immune-mediated cholangitis: is it always nivolumab’s fault? 146
Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response 146
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 144
Chemotherapy treatment in malignant pleural mesothelioma: A difficult history 143
Immune checkpoint inhibitors for metastatic bladder cancer 143
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 143
Second-line treatment of advanced non-small cell lung cancer 142
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases 139
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 139
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer 138
Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer 138
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 137
Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role? 137
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 137
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting 136
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 136
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC 135
ALK rearrangement testing by fish analysis in non-small-cell lung cancer patients: Results of the first Italian external quality assurance scheme 135
Colorectal cancer patient on maintenance dialysis successfully treated with cetuximab 135
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 134
Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: A Phase II Study 134
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 134
SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor 134
Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling 134
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 133
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 133
Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH 132
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 132
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 132
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 132
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): An open-label randomised controlled phase 3 trial 131
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 130
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 130
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 130
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program 130
Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab 130
Thoracic myopericytoma in an older adult, rare but possible: A case report 129
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 129
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 129
Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study 128
Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma 128
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study 127
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 127
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 127
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 126
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016 125
Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study 125
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 125
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956) 125
Totale 16.420
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.788
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.788
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.537 0 0 0 0 0 129 95 217 427 209 148 1.312
2021/20224.862 428 169 322 249 550 247 139 536 275 195 933 819
2022/20235.163 431 694 264 635 454 411 250 313 906 130 354 321
2023/20241.750 155 274 106 147 120 235 64 275 69 137 109 59
2024/20257.007 270 1.113 619 486 957 401 568 205 128 536 403 1.321
2025/20268.639 1.677 1.983 1.535 1.114 1.789 541 0 0 0 0 0 0
Totale 39.968